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Abstract
Background: No efficacy studies of influenza vaccination given to GPs have yet been published.
Therefore, our purpose was to assess the effect of an inactivated influenza vaccine given to GPs on
the rate of clinical respiratory tract infections (RTIs) and proven influenza cases (influenza positive
nose and throat swabs and a 4-fold titre rise), while adjusting for important covariates.
Methods: In a controlled trial during two consecutive winter periods (2002–2003 and 2003–2004)
we compared (77 and 100) vaccinated with (45 and 40) unvaccinated GPs working in Flanders,
Belgium. Influenza antibodies were measured immediately prior to and 3–5 weeks after vaccination,
as well as after the influenza epidemic. During the influenza epidemic, GPs had to record their
contact with influenza cases and their own RTI symptoms every day. If they became ill, the GPs had
to take nose and throat swabs during the first 4 days. We performed a multivariate regression
analysis for covariates using Generalized Estimating Equations.
Results:  One half of the GPs (vaccinated or not) developed an RTI during the 2 influenza
epidemics. During the two influenza periods, 8.6% of the vaccinated and 14.7% of the unvaccinated
GPs had positive swabs for influenza (RR: 0.59; 95%CI: 0.28 – 1.24). Multivariate analysis revealed
that influenza vaccination prevented RTIs and swab-positive influenza only among young GPs
(ORadj: 0.35; 95%CI: 0.13 – 0.96 and 0.1; 0.01 – 0.75 respectively for 30-year-old GPs).
Independent of vaccination, a low basic antibody titre against influenza (ORadj 0.57; 95%CI: 0.37 –
0.89) and the presence of influenza cases in the family (ORadj 9.24; 95%CI: 2.91 – 29) were highly
predictive of an episode of swab-positive influenza.
Conclusion: Influenza vaccination was shown to protect against proven influenza among young
GPs. GPs, vaccinated or not, who are very vulnerable to influenza are those who have a low basic
immunity against influenza and, in particular, those who have family members who develop
influenza.
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Background
There are two important issues when considering influ-
enza vaccination of general practitioners (GPs) as advo-
cated by many guidelines. [1,2] Firstly, an influenza
vaccine must give personal protection to the GP. To a cer-
tain extent, this issue has been addressed by efficacy stud-
ies among healthy adults. [3] Secondly, vaccination might
be useful for preventing transmission of influenza
between GPs and their patients. For example, in long-term
care hospitals, influenza vaccination of healthcare work-
ers reduced mortality among the elderly. [4,5]However,
owing to the low basic immunity against influenza among
healthy adults and healthcare workers working in long-
term care facilities, the results of these studies are not fully
applicable to general practice.
Since GPs have frequent close contact with many influ-
enza cases, they build up a high basic immunity and prob-
ably only suffer from minor symptoms. [6,7]Whether the
vaccine adds substantial benefit to this naturally acquired
immunity is unknown. Inactivated vaccines are not very
useful in preventing cross-infection and the shedding of
viruses from the nose and throat; [8,9]they are only
known to diminish the severity of the influenza symp-
toms and to prevent complications, especially when com-
pared to intra-nasally administered influenza vaccines
(inactivated whole virus, [10]with adjuvants, [11]or live
cold-adapted) [9]that elicit a better local immune
response (mucosal IgA) in the nose, throat and airways.
Unfortunately, these new vaccines are not yet commer-
cially available in Europe.
Until now, no efficacy studies of influenza vaccination
among GPs have been published. Therefore, our purpose
was to assess the effect of an inactivated influenza vaccine
given to GPs on clinical respiratory tract infections (RTIs)
and, more particularly, against influenza cases with influ-
enza-positive nose and throat swabs (diagnosed by
reverse transcriptase polymerase chain reaction RT-PCR),
in addition to serologically-defined influenza cases. We
also adjusted for relevant covariates.
Methods
1. Design of the study
A controlled trial during two consecutive winter periods
(2002–2003 and 2003–2004) was performed, comparing
vaccinated and unvaccinated GPs working in Flanders
recruited on a voluntary basis in July and August 2002 and
2003. First-year participants were asked to re-enter the
study during the second winter period. Subjects were
enrolled after giving their written informed consent. The
study was approved by the Medical Ethics Committee of
the University Clinic of Antwerp. Participating GPs had to
fill in a questionnaire relating to their general characteris-
tics and previous influenza vaccinations. Owing to ethical
considerations, the GPs were free to choose whether or
not to receive an influenza vaccination during the study
period. Those who wanted to be vaccinated were
instructed to have the 0.5-ml vaccine administered into
the deltoid muscle, at the end of October of each study
year. GlaxoSmithKline n.v. provided Alfarix®, a commer-
cially available non-adjuvant trivalent inactivated split-
influenza vaccine, to each participating GP personally for
this study. In 2002 – 2003 and 2003 – 2004 the vaccine
contained the same strains: 15 µg hemagglutinin from A/
New Caledonia/20/99 (H1N1), A/Moscow/10/99 (= A/
Panama/2007/99) (H3N2) and B/Hong Kong/330/2001.
2. Blood collection and serology
Blood specimens for the antibody studies were taken
immediately prior to and 3–5 weeks after vaccination.
Unvaccinated GPs only gave 1 blood specimen in Novem-
ber before the influenza epidemic, assuming this would
give the same antibody titres as blood samples taken one
month earlier (= pre-epidemic).
Three weeks after the influenza epidemic, both groups
gave another blood specimen (= post-epidemic). The
blood samples were collected by local medical laborato-
ries for serum extraction and preservation (-20°C). After
the last blood sample was taken, the serum tubes were
transported to Viroclinics in Rotterdam.
Viroclinics did a hemagglutination-inhibition (HAI) test
using standard methods to measure the influenza anti-
body titre against the circulating influenza strains. In
2002–2003, antibody titres were determined against A/
H1N1 (IVR-116), A/H3N2 (ResVir-17) and B/Shang-
dong/7/'97. In 2003–2004, only one strain was circulat-
ing and therefore only the titre against A/H3N2 (Fujian-
like) was measured. Each test was performed twice and the
average titre was taken as the outcome. Laboratory per-
sonnel were blinded to the identity and study group of the
serum samples. We considered a 4-fold or greater titre rise
detected in the paired samples collected at any time
between pre- and post-epidemic periods as indicative of
an immune reaction following an influenza virus infec-
tion.
3. Daily diary recording
For 60 consecutive days (weekends and holidays
included), the GPs were asked to complete diaries.
Instruction to start daily diary entries was given as soon as
the Scientific Institute of Public Health (IPH – http://
www.iph.fgov.be/flu) in Brussels detected the first influ-
enza viruses in nose and throat swabs collected by sentinel
physicians in Belgium during two successive weeks (Fig-
ure 1). In the 2002–2003 winter period, diary recording
started on February 13, 2003 (7th week); in the 2003–BMC Medicine 2006, 4:17 http://www.biomedcentral.com/1741-7015/4/17
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2004 winter period, diary recording was started much ear-
lier, on November 22, 2003 (47th week).
The GPs were asked to record the number of contacts with
patients in general and with those diagnosed as influenza
cases (patients, family and other contacts) in particular.
The GPsalso had to report the number of influenza
patients whomthey hadseenfor another reason within a
week prior to having diagnosedthe patients with influ-
enza. An influenza case was defined as any person for
whom the GP established a clinical diagnosis of influenza
on the basis of the following symptoms and signs: sudden
onset, high fever (above 38°C), cough and myalgia.
GPs suffering from the slightest symptom of an RTI had to
mention this in their diaries and record their oral body
temperature, and also to record the severity of their own
signs and symptoms. Furthermore, affected GPs had to
indicate their diagnosis, their medication, and any sick
leave taken.
After the recording periods ended, the diaries were sent by
post (2002–2003) or collected personally (2003–2004).
4. Influenza virus detection
GPs were asked to brush their nose with two cotton swabs
and their throat with 1 cotton swab from the first to the
fourth day during each RTI that they developed during the
recording period. The swabs were immersed in a transport
medium (Earle's minimal essential medium (EMEM)
with addition of antibiotics and antimycotic products)
and were stored by the local medical laboratory where the
samples were collected by a courier of the Scientific Insti-
tute of Public Health (IPH). After the influenza epidemic,
the transport media were analysed with a nested RT-PCR
test first to distinguish between A and B strains, and then
to subtype the A strains as H3 or H1. Uncertain results
were retested. Laboratory personnel were blinded to the
identity and study group of the swabs.
5. Statistics
A preliminary sample size estimation was performed
using Epi-info. If we assumed a clinically significant vac-
cine efficacy of 70% in preventing influenza and an inci-
dence of serologically-defined influenza in the
unvaccinated group of 23%, [7]or an incidence as defined
by virus detection (RT-PCR) of 8.5% (result of a pilot
The incidence of influenza-like illnesses (ILI) and acute respiratory infections (ARI) recorded by sentinel physicians in Belgium Figure 1
The incidence of influenza-like illnesses (ILI) and acute respiratory infections (ARI) recorded by sentinel physicians in Belgium.BMC Medicine 2006, 4:17 http://www.biomedcentral.com/1741-7015/4/17
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study), then we needed 124 and 368 vaccinated GPs and
62 and 184 unvaccinated GPs respectively (a 2:1 ratio) for
a power of 80% and a two-sided significance level of 0.05.
Differences in proportions were assessed by Pearson χ2
tests and odds ratios (95%CI); continuous variables were
analysed by Student's t-tests after converting serum titres
to the natural logarithm using SPSS version 12.0.
We performed a multivariate regression analysis for rele-
vant covariates using Generalized Estimating Equations
(GEE) (GENMOD in SAS statistics version 8.02) follow-
ing the Hierarchical Backward Elimination Approach of
Kleinbaum [12]to determine which factors other than
vaccination influence the three dichotomous outcomes
defined as RTIs in general, RTIs with influenza-positive
nose and throat swabs, and RTIs with influenza-positive
nose and throat swabs and/or a 4-fold titre rise. Con-
founding variables of interest included: study year; age in
years; basic immunity (lnT1); mean number of patient
contacts/day; mean number of influenza patients/day;
family members with influenza; colleagues with influ-
enza; having young children (<7 years); and working in a
Child and Family preventive medicine facility (Table 3).
In addition, significant interaction terms between vacci-
nation and these confounding variables were introduced
in the model.
Results
1. General characteristics
A total of 122 GPs, of whom 77 were vaccinated against
influenza in October 2002, were included in the first part
of the study, while 140 GPs, of whom 100 were vaccinated
in October 2003, participated in the second part. Overall,
72 GPs participated in both parts. Missing and eliminated
data (diaries and serology) are shown in Figure 2.
In 2003, we had to consider 47 (46 vaccinated) second
serum samples to be missing because these were taken
during the influenza epidemic that started as early as
Flowchart of GPs' missing diaries and serology data Figure 2
Flowchart of GPs' missing diaries and serology data.
2002 2003
n=140
VAC
n=100
UNVAC
n=40
missing diaries
n=40
-4
n=96
missing pre-vac titre -6
missing pre-vac, pre-
and post-epidemic titre
-14 -3
pre-epidemic titre taken 
during flu period
-46 -1
n=30
n=122
VAC
n=77
UNVAC
n=45
n=36
missing diaries -11 -10
n=66 n=35
-4 missing pre-vac titre
-5 -1 missing pre-epidemic 
titre
-1 pre-epidemic titre taken 
during flu period
-1 -1 missing post-epidemic
titre
n=55 n=33BMC Medicine 2006, 4:17 http://www.biomedcentral.com/1741-7015/4/17
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November 22, 2003. Thirteen sick GPs in 2002 and 11
sick GPs in 2003 did not take nose and throat swabs as
requested.
Table 1 shows that most characteristics did not differ
between the vaccinated and unvaccinated groups. There
were fewer patient contacts in the unvaccinated group: in
2002 and 2003, 21 and 20 patients/day in the vaccinated
group versus 18 and 17 patients/day in the unvaccinated
group, respectively (p < 0.05). As expected, the vaccinated
group was also highly vaccinated against influenza in pre-
vious years: more than 80% versus less than 20% in the
unvaccinated group (p < 0.0001). Consequently, in the
first serum sample, higher geometric mean serum anti-
body titres (GMT) were measured in the vaccinated group:
in 2002, 125 versus 77 (p < 0.05); in 2003, 54 versus 22
(p < 0.0001). The vaccinated GPs also had a higher sero-
protection level (number of GPs with a baseline titre >
40): in 2002, 91% versus 80% (NS); in 2003, 70% versus
42% (p < 0.05).
2. Efficacy and effectiveness of influenza vaccination
In 2002 and 2003, more than half the GPs suffered at least
once from an RTI (mild infections included). Overall,
influenza vaccination of GPs had no efficacy in preventing
RTIs in general in 2002 or 2003 (Table 2). In 2002, only
about 5% of vaccinated GPs and 6% of unvaccinated GPs
had positive swabs. However, in 2003, 12% of vaccinated
GPs had positive swabs compared with 23% of unvacci-
nated GPs. The efficacy (= 100(1 – RR)) of vaccination in
preventing positive nose and throat swabs showed an
increasing trend from 22% in 2002 to 49% in 2003, but
this trend was not statistically significant, even when both
years (41%) were combined. When the results of both
years were combined, vaccination had a significant effect
on the 4-fold titre rise alone (72%; 95%CI: 25–90%) and
in combination with positive swabs (56%; 95%CI: 12–
78%). For these comparisons, possible confounders were
not taken into account.
The mean of the highest body temperature of every RTI
episode was 37.4°C in the influenza infections (positive
Table 1: General characteristics of participating GPs: figures are numbers (percentage) unless stated otherwise.
2002 2003
VAC UNVAC VAC UNVAC
General
Men 50/77 (64.9) 25/45 (55.6) 61/100 (61.0) 18/40 (45.0)
Mean (SE) of age 42.4 (1.1) 40.0 (1.5) 43.1 (0.9) 41.3 (10.8)
Influenza vaccine 1 and 2 years before 60/77 (77.9) 3/43 (7.0) ‡ 67/94 (71.3) 3/38 (7.9) ‡
Influenza vaccine 1 year before 66/77 (85.7) 3/44 (6.8) ‡ 78/95 (82.1) 3/39 (7.7) ‡
Influenza vaccine 1, 2, and 3 years before 54/71 (76.1) 1/42 (2.4)‡ 62/91 (68.1) 3/38 (7.9) ‡
Influenza vaccine 2 years before 64/77 (83.1) 8/43 (18.6) ‡ 73/94 (77.7) 3/38 (7.9) ‡
Influenza vaccine 3 years before 59/71 (83.1) 6/42 (14.3) ‡ 73/91 (80.2) 4/38 (10.5) ‡
Influenza disease 1 year before 9/75 (12.0) 7/42 (16.7) 11/93 (11.8) 4/38 (10.5)
Working in Child and Family preventive medicine facility 11/75 (14.7) 4/45 (8.9) 13/100 (13.0) 4/40 (10.0)
Having young children < 7 years of age 20/70 (28.6) 14/44 (31.8) 21/98 (21.4) 10/40 (25.0)
Smoking 7/72 (9.7) 3/42 (7.1) 9/96 (9.4) 1/39 (2.6)
Allergy 21/72 (29.2) 9/42 (21.4) 23/94 (24.5) 6/38 (15.8)
Seroprotection at baseline1 against A:/H3N2 61/67 (91.0) 31/39 (79.5) 56/80 (70.0) 15/36 (41.7) †
GMT12 A:/H3N2 (SE) 125.39(1.12) 77.26 (1.19) † 54.25 (1.14) 22.34 (1.23) ‡
Information from the diaries
GPs with family members with influenza 34/66 (51.5) 19/35 (54.3) 54/96 (56.3) 20/40 (50.0)
GPs with colleagues with influenza 23/66 (34.8) 12/35 (34.3) 35/96 (36.5) 15/40 (37.5)
Mean (SE) number of patient contacts/day 21.3 (1.0) 17.9 (1.3) † 20.4 (0.8) 16.6 (1.2) †
Mean (SE) number of patients with influenza/day 1.6 (0.2) 1.7 (0.2) 2.0 (0.2) 2.1 (0.3)
1number of GPs with a baseline titre (T1) > 40
2 geometric mean baseline titre (T1)
† p-value < 0.05
‡ p-value < 0.0001BMC Medicine 2006, 4:17 http://www.biomedcentral.com/1741-7015/4/17
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swabs); this was statistically significantly higher than dur-
ing the other RTIs (p = 0.005). In general, the influenza
infections lasted 2 days longer (p = 0.03). Of the GPs with
positive swabs, 20% took sick leave, compared to 12% of
GPs suffering from other RTIs (p = 0.3).
3. Multivariate analysis
Table 3 shows the results of the multivariate regression
analysis for correlated data for the 3 dichotomous out-
comes defined as RTIs in general, RTIs with influenza-pos-
itive nose and throat swabs, and RTIs with influenza-
positive nose and throat swabs and/or a 4-fold titre rise.
For the first two outcomes, vaccine*age was the only sig-
nificant interaction term (Wald p < 0.02). Therefore, this
interaction term yielded different effect sizes of influenza
vaccination for different age groups. For example, influ-
enza vaccination of 30-year-old GPs was effective, inde-
pendent of the definition of the outcome. At this age, the
efficacy of the vaccine in preventing positive nose and
throat swabs was as high as 90%. However, at 50 years of
age, influenza vaccination had no effect (OR>1), except in
preventing influenza cases defined as positive swabs and/
or a 4-fold titre rise. For preventing proven swab-positive
influenza, the OR was statistically significant under 36
years of age (OR 0.22; 95%CI: 0.04 – 1.06) and became 1
at 48 years of age (Figure 3). Other than vaccination, no
other variable had an important effect on RTIs in general.
More specifically, the prevention of positive swabs and/or
a 4-fold titre rise depended on the basic immunity against
influenza reflected in this model by the natural logarithm
of the A/H3N2 influenza antibody titre of the first serum
sample (OR for a difference of 1 in lnT1 = 0.57; 95%CI:
0.38 – 0.86). In addition, the presence of family members
with influenza was highly predictive for retrieving positive
nose and throat swabs and/or a 4-fold titre rise (OR =
3.62; 95%CI: 1.20 – 10.89). Careful review of the diary
data revealed that 20 of 25 PCR-proven influenza cases
had a family member who was also affected. In 13 cases,
the family member was ill prior to the GP, and in 3 cases
concurrently with the GP.
Discussion
Multivariate analysis revealed that influenza vaccination
prevented both respiratory tract infections in general and
proven influenza during an influenza epidemic, especially
among young general practitioners. Independently of vac-
The effect of influenza vaccination (OR) on respiratory tract  infections with influenza-positive nose and throat swabs for  different ages: multivariate regression analysis Figure 3
The effect of influenza vaccination (OR) on respiratory tract 
infections with influenza-positive nose and throat swabs for 
different ages: multivariate regression analysis.
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Table 2: Efficacy and effectiveness of influenza vaccination according to different outcomes: crude results
VAC UNVAC RR 95% Cl
Number of GPs with a respiratory tract infection 2002 37/66 (56.1%) 21/35 (60%) 0.93 0.66 – 1.32
2003 48/96 (50%) 19/40 (47.5%) 1.05 0.72 – 1.54
2002–2003 85/162 (52.5%) 40/75 (53.3%) 0.98 0.76 – 1.27
Number of GPs with a respiratory tract infection and positive 
nose and throat swabs
2002 3/66 (4.5%) 2/35 (5.7%) 0.78 0.13 – 4.94
2003 11/96 (11.5%) 9/40 (22.5%) 0.51 0.23 – 1.13
2002–2003 14/162 (8.6%) 11/75 (14.7%) 0.59 0.28 – 1.24
Number of GPs with a respiratory tract infection and a 4-fold 
hemagglutination-inhibition antibody titre rise
2002 2/59 (3.4%) 4/33 (12.1%) 0.28 0.05 – 1.45
2003 3/36 (8.3%) 9/36 (25%) 0.33 0.10 – 1.13
2002–2003 5/95 (5.3%) 13/69 (18.8%) 0.28 0.10 – 0.75
Number of GPs with a respiratory tract infection and positive 
swab or 4-fold hemagglutination-inhibition antibody titre rise
2002 4/59 (6.8%) 6/33 (15.2%) 0.45 0.13 – 1.55
2003 7/36 (19.4%) 13/36 (36.1%) 0.54 0.24 – 1.19
2002–2003 11/95 (11.6%) 18/69 (26.1%) 0.44 0.22 – 0.88BMC Medicine 2006, 4:17 http://www.biomedcentral.com/1741-7015/4/17
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cination, a low basic antibody titre against influenza and
the presence of influenza cases in the family were highly
predictive of an episode of influenza with positive swabs
and/or a 4-fold titre rise.
During the recording periods in both years, half the GPs
had some form of RTI. That 50% of GPs were affected by
RTIs seems rather high, but could be explained by the fact
that even mild symptoms were recorded and reflects the
occurrence of mild infections through which natural
immunity is constantly updated. The general RTI defini-
tion used in this study was too imprecise to allow a signif-
icant vaccination effect to be shown.
Our study was slightly underpowered for demonstrating
statistically significant efficacy of an influenza vaccination
in preventing RTIs with RT-PCR-positive nose and throat
swabs. There was a large difference in efficacy between the
two years: 22% in 2002 and 49% in 2003. Furthermore,
in the unvaccinated group, the incidence of positive influ-
enza cases rose from 5% in 2002 to 23% in 2003. During
the first study period (2002), there was a high basic
immunity against influenza A as the cumulative result of
the previous 2 years in which the circulating influenza
virus A strains did not change much. [13]According to the
IPH, the peak incidence of influenza-like illnesses in the
community was 5% in week 9 in the first study year and
10% in week 50 of the following influenza season (2003–
2004) [14](Figure 1). During 2003/2004, a slightly differ-
ent influenza A virus was circulating. Although this new
A/Fujian-like A/H3N2 virus was different from the A
strains contained in the vaccine, the vaccine elicited a
good immune response. [15,16]An epidemiological study
performed among GPs during the Asian influenza epi-
demic of 1957 concluded that, in many parts of Britain,
doctors were exposed to a risk of influenza at least double
that of the general population in their practices. [17]
The RT-PCR test is more sensitive than a virus culture,
[4,18]since it also detects dead virus particles and is not
Table 3: Effect of influenza vaccination on respiratory tract infections (RTIs) in general, with influenza positive swabs and/or 4-fold titre 
rise: multivariate regression analysis for correlated data (GEE)
Outcome RTI in general (n = 202) RTI with positive swabs 
for influenza (n = 202)
RTI with pos swabs and/or 4-fold 
titre rise for influenza (n = 150)
Parameter1 OR 
estimate
95%CI OR 
estimate
95%CI OR 
estimate
95%CI
Lower 
limit
Upper 
limit
Lower 
limit
Upper 
limit
Lower 
limit
Upper 
limit
Vaccine†2 when GP is 30 years old 0.35 0.13 0.96 0.1 0.01 0.75 0.13 0.02 0.98
Vaccine† when GP is 50 years old 1.79 0.80 4.00 1.41 0.35 5.76 0.82 0.21 3.25
Co-variates
Year 2002/2003 0.98 0.49 1.96 0.42 0.13 1.42 0.52 0.18 1.53
Age‡3 0.49 0.17 1.43 0.58 0.17 1.96 0.37 0.09 1.53
Gender† 0.60 0.33 1.10 0.96 0.29 3.23 0.99 0.33 2.94
Basic immunity (natural logarithm of 
titre1)‡4
1.18 0.91 1.55 0.57 0.37 0.89 0.57 0.38 0.86
Mean number of patient contacts/day‡5 1.17 0.50 2.76 1.77 0.47 6.69 3.13 0.69 14.11
Mean number of contacts with influenza 
patients/day‡6
0.67 0.44 1.00 0.33 0.10 1.12 0.39 0.13 1.16
Family members with influenza† 1.88 0.97 3.64 9.24 2.91 29.40 3.62 1.20 10.89
Colleagues with influenza† 1.10 0.60 2.01 0.60 0.19 1.84 0.71 0.25 2.04
Having young children < 7 years of age† 2.00 0.95 4.24 1.37 0.42 4.52 1.04 0.30 3.67
Working in Child and family preventive 
medicine facility†
0.76 0.31 1.87 1.76 0.52 5.92 1.15 0.28 4.66
† dichotomous yes(1), no(0)
‡ continuous
1Intercept = 0.96 -1.63 3.54 0.68 -2.24 3.61 2.44 -1.41 6.28
2 Crude OR vaccine = 0.97 0.56 1.67 0.55 0.24 1.28 0.35 0.15 0.79
3 OR for difference of 20 years
4 OR for a difference of 1 in natural 
logarithm of titre1
5 OR for a difference of 20 patients
6 OR for a difference of 2 influenza patientsBMC Medicine 2006, 4:17 http://www.biomedcentral.com/1741-7015/4/17
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quantitative. Therefore, no conclusions can be drawn
about the degree of infectivity of the GPs with positive
nose and throat swabs. No significant difference was seen
between the GPs with infectious influenza and the other
GPs with RTIs with respect to comparing the number of
patients diagnosed with influenza and seen by the GP 1
week before for another reason, and 14 days before and
after the GP became ill.
This study confirmed the efficacy of influenza vaccination
on serologically-defined influenza; the efficacy of influ-
enza vaccination was 72% for the 2 years combined,
which is comparable with an efficacy of 88% (95%CI: 47–
97%) in preventing a 4-fold titre rise against A/H3N2
reported by Wilde et al. [19]Since no studies of the effi-
cacy of influenza vaccination among GPs have previously
been published, we can only compare our results with tri-
als performed among other healthcare professionals
working in hospitals. A Cochrane review dealing with vac-
cines given to prevent influenza in healthy adults
included the results of trials involving healthcare workers.
[3]None of these studies demonstrated significant efficacy
of influenza vaccination on influenza cases (clinically
defined and sometimes serologically confirmed), and
none of the studies presented results that evaluated the
ability of vaccination to interrupt the spread of the disease
(see [additional file 1]: existing literature concerning our
study results.)
Multivariate analysis revealed that the effect of influenza
vaccine decreased with age. Young GPs have a higher inci-
dence of influenza, and they have families with young
children. [20]Although these findings need to be con-
firmed by larger studies, they suggest that young GPs
should be the first to be vaccinated against influenza.
Medical students and postgraduate trainees would also
benefit from being among the first to be vaccinated.
However, the question arises as to whether influenza vac-
cination can be stopped at a certain age. It is likely that
GPs who have been working for more than 20 years in
full-time practice and who have enough yearly contact
with influenza patients do not need to be vaccinated.
Healthcare workers with fewer patient contacts need influ-
enza vaccination throughout their entire career. [21]These
considerations are only applicable in the inter-pandemic
period. When a new virus emerges, such as an adapted
avian influenza virus, and then when an appropriate vac-
cine is available, all healthcare workers, without excep-
tion, would be a priority group for vaccination.
The level of anti-hemagglutinin antibody titres before vac-
cination is another independent protective variable that
has been known for quite some time. [22]It was relatively
high in our GP population and reflects the cumulative
effect of previous vaccinations and natural infections.
[16]In our study, age was not related to the antibody titre
levels before the influenza epidemic. In addition to sero-
logical immunity, other immune factors, such as cellular
[23]and local mucosal immunity, which were not meas-
ured in this study, may play an important role. [10]
Another underestimated factor is the infectiousness of
family members with influenza. Independently of age or
vaccination status, sick family members, especially chil-
dren, were found to be very contagious. This result is not
new, [24,25]but the consequences have been minimized.
Among GPs during the 1957 Asian influenza epidemic, it
was noted that 9 of 19 GPs with a typical influenza attack
had a family member who had influenza. The authors
concluded that GPs were liable to be infected with influ-
enza at home, even after avoiding infection for several
weeks during repeated daily contact with patients who
have influenza. [17]Neuraminidase-inhibitors could be
taken preventively by healthcare workers who have a fam-
ily member who most probably has influenza during an
influenza epidemic. [26]Treating GPs only when they
already have influenza is not useful, as the signs and
symptoms will most likely be mild and non-specific, mak-
ing the diagnosis of influenza difficult. However, the use
of neuraminidase-inhibitors has already resulted in resist-
ant virus strains; [27]thus, prevention using a better-
designed vaccine is preferable.
Further research is needed, focusing particularly on assess-
ing the efficacy of new vaccines for use among healthcare
workers in preveningt influenza virus growth in the nose
and throat.
Some limitations of this study need to be considered. It
was underpowered for detecting a significant effect of
influenza vaccination on influenza cases with positive
nose and throat swabs; to detect an efficacy of 70% with a
measured incidence of proven influenza of 14.7% in the
unvaccinated group, at least 208 vaccinated and 104
unvaccinated GPs would have been needed. However, it
remains to be determined whether the efficacy in health-
care workers need not be higher to prevent possible infec-
tious cases of influenza and protect against transmission
to patients. If we assume an efficacy of 90% as clinically
relevant, we only needed 108 vaccinated and 54 unvacci-
nated GPs to participate in our study.
Unfortunately, the influenza epidemic started very early
in the second study year (November 22, 2003). Therefore,
47 serum samples taken after vaccination (T2) during this
epidemic were classified as missing. Titres measured in
these samples were significantly higher than those taken
before November 22, 2003. There were no differences
between the GPs with missing serum samples and thoseBMC Medicine 2006, 4:17 http://www.biomedcentral.com/1741-7015/4/17
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used in the analysis, except that fewer GPs with missing
serology had allergies; however, since allergy was not
related to the incidence of RTIs or influenza, this did not
affect the results. The only problem that remains is an
underestimation of influenza cases that were defined as a
4-fold titre rise after the epidemic. However, this defini-
tion of an influenza case remains questionable, especially
in a study group with high antibody titres before the influ-
enza epidemic. Since the unvaccinated group started with
a lower antibody titre, a greater number of 4-fold titre rise
cases could be expected in this group. Other authors
[7,19,28,29]have already mentioned this disproportion
and have noted that it is of no clinical importance.
In this article we did not focus on the immunogenetic
properties of the vaccine, [16]because knowing the effi-
cacy of the vaccine on clinical outcomes after an epidemic
challenge is far more appropriate for policy development.
Although the GPs in our study were not chosen at ran-
dom, we believe the results are representative. In fact, the
average age of the participants did not differ from national
averages. In 2003, slightly more women than average par-
ticipated in our study, but this was taken into account in
the multivariate analysis.
It is possible that a selection bias was introduced by hav-
ing the GPs themselves choose whether to be vaccinated.
Indeed, the most important difference between vacci-
nated and unvaccinated GPs was the number of influenza
vaccinations in previous years and their effect on basic
immunity. However, this too was taken into account in
the multivariate analysis.
Conclusion
Among general practitioners, the efficacy of an influenza
vaccination against proven influenza (virological and/or
serological defined) was rather moderate in this clinical
trial performed during two consecutive winter periods
(2002–2003); however, the efficacy was substantially
higher among younger GPs. Thus, younger GPs should be
the first to be vaccinated. Family members with influenza,
rather than the daily burden of influenza patients, make
every GP, vaccinated or not, very vulnerable to infectious
influenza. Every GP should be aware of this route of infec-
tion and should take adequate precautions.
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